Skip to main content
Erschienen in: Clinical Rheumatology 4/2011

01.04.2011 | Brief Report

Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis

verfasst von: Wei Wang, Jinming Li

Erschienen in: Clinical Rheumatology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Analysis of IgG subclass distribution of antibodies may provide insights into the mechanisms driving antibody production. Here, we have first determined IgG subclass distribution of anti-recombinant peptidylarginine deiminase 4 (anti-hPADI4) antibodies in sera from patients with rheumatoid arthritis (RA). Sera from 103 RA patients were screened to IgG anti-PADI4 using recombinant antigens. For positive samples, the subclass distribution of IgG anti-hPADI4 was determined by means of establishing the equipotency of four HRP-labeled IgG subclass-specific monoclonal antibodies. The subclass profiles were compared among individuals with different disease status. Thirty-three out of 103 RA patients were determined as IgG anti-hPADI4-positive. As expressed by percentage levels to total IgG anti-hPADI4 activity, IgG1 and IgG3 were determined to be the predominant subclasses of anti-hPADI4. Furthermore, distinct subclass distribution patterns were observed in patients with different disease status. The IgG subclass distribution of anti-hPADI4 indicates that a leading T lymphocyte-regulated IgG1 and IgG3 responses may contribute to a better understanding of the role of anti-PADI4 in RA.
Literatur
1.
Zurück zum Zitat Suzuki A, Yamada R, Yamamoto K (2007) Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann NY Acad Sci 1108:323–339PubMedCrossRef Suzuki A, Yamada R, Yamamoto K (2007) Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann NY Acad Sci 1108:323–339PubMedCrossRef
2.
Zurück zum Zitat Klareskog L, Widhe M, Hermansson M, Rönnelid J (2008) Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 20:300–305PubMedCrossRef Klareskog L, Widhe M, Hermansson M, Rönnelid J (2008) Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 20:300–305PubMedCrossRef
3.
Zurück zum Zitat Takizawa Y, Sawada T, Suzuki A, Yamada R, Inoue T, Yamamoto K (2005) Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol 34:212–215PubMedCrossRef Takizawa Y, Sawada T, Suzuki A, Yamada R, Inoue T, Yamamoto K (2005) Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol 34:212–215PubMedCrossRef
4.
Zurück zum Zitat Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegård S, Kvien TK, Molberg Ø (2008) Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis 67:414–417PubMedCrossRef Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegård S, Kvien TK, Molberg Ø (2008) Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis 67:414–417PubMedCrossRef
5.
Zurück zum Zitat Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø (2009) Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann Rheum Dis 68:249–252PubMedCrossRef Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø (2009) Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann Rheum Dis 68:249–252PubMedCrossRef
6.
Zurück zum Zitat Zhao J, Zhao Y, He J, Jia R, Li Z (2008) Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol 35:969–974PubMed Zhao J, Zhao Y, He J, Jia R, Li Z (2008) Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol 35:969–974PubMed
7.
Zurück zum Zitat Harris ML, Darrah E, Lam GK et al (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 58:1958–1967PubMedCrossRef Harris ML, Darrah E, Lam GK et al (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 58:1958–1967PubMedCrossRef
8.
Zurück zum Zitat Auger I, Balandraud N, Rak J, Lambert N, Martin M, Roudier J (2009) New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 68:591–594PubMedCrossRef Auger I, Balandraud N, Rak J, Lambert N, Martin M, Roudier J (2009) New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 68:591–594PubMedCrossRef
9.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
10.
Zurück zum Zitat van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850PubMedCrossRef van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850PubMedCrossRef
11.
Zurück zum Zitat Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatol Oxf 43:1252–1255CrossRef Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatol Oxf 43:1252–1255CrossRef
12.
Zurück zum Zitat Samarkos M, Davies KA, Gordon C, Walport MJ, Loizou S (2001) IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology Oxf 40:1026–1032CrossRef Samarkos M, Davies KA, Gordon C, Walport MJ, Loizou S (2001) IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology Oxf 40:1026–1032CrossRef
13.
Zurück zum Zitat Hamilton RG (1987) Human IgG subclass measurements in the clinical laboratory. Clin Chem 33:1707–1725PubMed Hamilton RG (1987) Human IgG subclass measurements in the clinical laboratory. Clin Chem 33:1707–1725PubMed
14.
Zurück zum Zitat Rubin RL, Tang FL, Chan EK, Pollard KM, Tsay G, Tan EM (1986) IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren’s syndrome, and drug-induced autoimmunity. J Immunol 137:2528–2534PubMed Rubin RL, Tang FL, Chan EK, Pollard KM, Tsay G, Tan EM (1986) IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren’s syndrome, and drug-induced autoimmunity. J Immunol 137:2528–2534PubMed
15.
Zurück zum Zitat Tokano Y, Yasuma M, Harada S, Takasaki Y, Hashimoto H, Okumura K, Hirose S (1991) Clinical significance of IgG subclasses of Anti-Sm and U1 ribonucleoprotein antibodies in patients with systemic lupus erythematosus and mixed connective tissue disease. J Clin Immunol 11:317–325PubMedCrossRef Tokano Y, Yasuma M, Harada S, Takasaki Y, Hashimoto H, Okumura K, Hirose S (1991) Clinical significance of IgG subclasses of Anti-Sm and U1 ribonucleoprotein antibodies in patients with systemic lupus erythematosus and mixed connective tissue disease. J Clin Immunol 11:317–325PubMedCrossRef
16.
Zurück zum Zitat Koga M, Yuki N, Hirata K, Morimatsu M, Mori M, Kuwabara S (2003) Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain–Barré syndrome. Neurology 60:1514–1518PubMed Koga M, Yuki N, Hirata K, Morimatsu M, Mori M, Kuwabara S (2003) Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain–Barré syndrome. Neurology 60:1514–1518PubMed
17.
Zurück zum Zitat de Haan S, Lahooti H, Morris O, Wall JR (2010) Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease. Autoimmunity. doi:10.3109/08916931003774954 PubMed de Haan S, Lahooti H, Morris O, Wall JR (2010) Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease. Autoimmunity. doi:10.​3109/​0891693100377495​4 PubMed
18.
Zurück zum Zitat Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K (2005) Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatol Oxf 44:40–50CrossRef Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K (2005) Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatol Oxf 44:40–50CrossRef
19.
Zurück zum Zitat Foulquier C, Sebbag M, Clavel C et al (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 56:3541–3553PubMedCrossRef Foulquier C, Sebbag M, Clavel C et al (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 56:3541–3553PubMedCrossRef
20.
Zurück zum Zitat Spiegelberg HL (1989) Biological role of different antibody classes. Int Arch Allergy Appl Immunol 90(Suppl 1):22–27PubMedCrossRef Spiegelberg HL (1989) Biological role of different antibody classes. Int Arch Allergy Appl Immunol 90(Suppl 1):22–27PubMedCrossRef
21.
22.
Zurück zum Zitat Cohen PL, Cheek RL, Hadler JA, Yount WJ, Eisenberg RA (1987) The subclass distribution of human IgG rheumatoid factor. J Immunol 139:1466–1471PubMed Cohen PL, Cheek RL, Hadler JA, Yount WJ, Eisenberg RA (1987) The subclass distribution of human IgG rheumatoid factor. J Immunol 139:1466–1471PubMed
23.
Zurück zum Zitat Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G (2005) IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 139:542–550PubMedCrossRef Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G (2005) IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 139:542–550PubMedCrossRef
24.
Zurück zum Zitat Engelmann R, Brandt J, Eggert M, Karberg K, Krause A, Neeck G, Mueller-Hilke B (2008) IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatol Oxf 47:1489–1492CrossRef Engelmann R, Brandt J, Eggert M, Karberg K, Krause A, Neeck G, Mueller-Hilke B (2008) IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatol Oxf 47:1489–1492CrossRef
Metadaten
Titel
Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis
verfasst von
Wei Wang
Jinming Li
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 4/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1671-4

Weitere Artikel der Ausgabe 4/2011

Clinical Rheumatology 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.